Talis Biomedical Corporation Expands in Chicago at Trammell Crow Company’s Fulton Labs at 1375 W. Fulton
January 27, 2021
The new tenant marks the third life science firm to sign a lease at Fulton Labs campus in less than six months.
Trammell Crow Company (TCC), one of the largest commercial real estate developers in the United States, today announced that it has signed Talis Biomedical Corporation as a tenant at its Fulton Labs at 1375 W. Fulton development. Talis will join other leading life sciences companies, including Xeris Pharmaceuticals and Portal Innovations, that call Fulton Labs home.
Talis, represented by David Saad and Chad Freese with CBRE, will occupy 26,432 square feet of advanced lab, office and chemical storage space. The new lease expands Talis’ presence in Chicago and complements their current operations in California.
Fulton Labs at 1375 W. Fulton is part of TCC’s 725,000-square-foot Fulton Labs campus —offering the most advanced lab spaces with next-generation technology and invigorating amenities for health and life sciences companies in Chicago’s Fulton Market neighborhood. The campus is comprised of the 300,000-square-foot building at 1375 W. Fulton and a 425,000-square-foot building nearby at 400 N. Aberdeen, which broke ground in July 2020. TCC anticipates the latter best-in-class laboratory facility to be complete by early 2022.
“We made the decision to bet on Chicago because we knew how incredible the depth of life sciences talent and demand for advanced R&D lab space was in the area,” said Johnny Carlson, Principal at TCC “With Fulton Labs, our goal is provide the infrastructure needed to retain and attract life sciences talent to this region. With more than 82,000 square feet leased in just the last six months of otherwise sluggish market activity, it is clear that we are providing Chicago a prime destination for life science innovation.”
Chicago’s abundance of major research institutions, universities and Fortune 100 life and health sciences companies provides the region with an incredible talent pool, making it a hotbed for investment and innovation. According to CBRE research., over the past three years, Chicago has had the largest percentage increase in life sciences venture capital of any major U.S. market. These factors have fueled major growth in the Chicago life sciences industry, along with demand for lab space in the region.
TCC selected CBRE’s leading Life Sciences Leasing Team to support its development team in marketing Fulton Labs for lease. For all campus leasing inquiries, contact Dan Lyne at [email protected] or Kelsey Scheive at [email protected].
Trammell Crow Company
Trammell Crow Company (TCC) is a global commercial real estate developer and wholly-owned subsidiary of CBRE Group, Inc. (NYSE:CBRE), a Fortune 500 and S&P 500 company headquartered in Dallas. Founded in 1948, TCC has developed or acquired nearly 2,900 buildings valued at $75 billion and over 655 million square feet. As of September 30, 2023, TCC had $15.4 billion of projects in process and $14.5 billion in its pipeline. It employs 650 professionals in 28 major cities throughout the United States and Europe. The company serves users of and investors in office, industrial/logistics, healthcare, life sciences and mixed-use projects, as well as multi-family residential through its operating subsidiary High Street Residential. For more information visit www.TrammellCrow.com.